{"groups":[{"description":"Amivantamab weekly for the first cycle and biweekly thereafter.\n\nAmivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).","id":"FG000","title":"Amivantamab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Twenty-six patients were screened for eligibility, and 5 patients did not meet screening criteria. Twenty-one patients began protocol treatment and were included in the safety set, while 3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging"}